David Whitlock

AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.

AOBiome LLC develops and commercializes skin care products. The firm operates an application of AOB that has the potential to restore critical biological and biochemical processes through the symbiotic relationship between humans and this naturally-existing bacteria to address significant clinical need. It has six ongoing clinical programs in acne vulgaris, or acne, allergic rhinitis, migraine, atopic dermatitis, or eczema, rosacea and hypertension, and multiple ongoing preclinical programs, including pulmonary and gastrointestinal disorders. The company was founded by Jamie Heywood, Lenny Barshack, Spiros Jamas, and David Whitlock in 2013 and is headquartered in Cambridge, MA.